Results 131 to 140 of about 5,232 (145)

Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate in the GOLDEN 3 and 4 Studies

B64. COPD: MECHANISM AND TREATMENT, 2019
J.A. Ohar, A. Ozol-Godfrey, T. Goodin, S. Sanjar   +3 more
openaire   +1 more source

Analysis of Patient Characteristics and Peak Inspiratory Flow Rates in Three Phase 3 Trials of Nebulized Glycopyrrolate in Moderate to Very Severe COPD

Chest, 2017
Donald Mahler, Barry Price, Robert Tosiello, Sanjay Sharma   +3 more
openaire   +1 more source

The Efficacy and Safety of a Novel, Nebulized Glycopyrrolate for the Treatment of COPD in Phase 3 Placebo-Controlled Studies: Effect of Baseline Lung Function and Age

Chest, 2017
Jill Ohar, Thomas Goodin, Shahin Sanjar
openaire   +1 more source

Efficacy and Safety of Nebulized Glycopyrrolate/eFlow® Closed System in Patients with Moderate-to-Very-Severe Chronic Obstructive Pulmonary Disease with Pre-Existing Cardiovascular Risk Factors

Chronic Obstructive Pulmonary Diseases (Miami, Fla ), 2019
Robert Tosiello, Shahin Sanjar, Gary T Ferguson   +2 more
exaly  

Nebulized glycopyrrolate (Lonhala Magnair) for COPD.

The Medical letter on drugs and therapeutics, 2018
openaire   +1 more source

Effect of Metabolic Syndrome Status on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate in the GOLDEN 3 and 4 Studies

B64. COPD: MECHANISM AND TREATMENT, 2019
B. Carlin, G.T. Ferguson, A. Ozol-Godfrey, T. Goodin, S. Sanjar   +4 more
openaire   +1 more source

Glycopyrrolate/eFlow CS: The First Nebulized Long-Acting Muscarinic Antagonist Approved to Treat Chronic Obstructive Pulmonary Disease

Annals of Pharmacotherapy, 2019
Roy Pleasants
exaly  

In Vitro Characterization of the eFlow Closed System Nebulizer with Glycopyrrolate Inhalation Solution

Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2018
Edward M Kerwin, Gary T Ferguson, Thomas Goodin   +2 more
exaly  

Clinically Important Deterioration Among Patients with Chronic Obstructive Pulmonary Disease (COPD) Treated with Glycopyrrolate Eflow® Closed System (CS) (nebulized Glycopyrrolate) in Pooled Data from Two Randomized, Double Blind, Placebo-Controlled Studies

C32. COPD: TRANSLATIONAL AND MECHANISTIC STUDIES, 2019
E.M. Kerwin, L. Murray, V. Ganapathy, C. Dembek, K. Rajagopalan   +4 more
openaire   +1 more source

The Effect of Baseline Rescue Medication Use on Lung Function and Patient-Reported Outcomes in Patients with COPD Treated with Nebulized Glycopyrrolate in the GOLDEN 3 and 4 Studies

B64. COPD: MECHANISM AND TREATMENT, 2019
J.F. Donohue, A. Ozol-Godfrey, T. Goodin, S. Sanjar   +3 more
openaire   +1 more source